AKAP7

Across TCGA pan-cancer cohorts, AKAP7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AKAP7 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher AKAP7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AKAP7 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, CCRCC, and LUAD are the cancer types where AKAP7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.758	0.345	<.001	29	view →
CCRCC	DFS	Median	III,IV	0.399	0.932	.022	6	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AKAP7–GBM (OS)

Open the GBM breakdown →